X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (39) 39
index medicus (38) 38
female (37) 37
breast cancer (36) 36
oncology (30) 30
adult (24) 24
middle aged (24) 24
article (22) 22
breast neoplasms - pathology (18) 18
aged (17) 17
chemotherapy (17) 17
cancer (16) 16
breast neoplasms - drug therapy (15) 15
radiology, nuclear medicine & medical imaging (12) 12
treatment outcome (11) 11
breast neoplasms - metabolism (10) 10
breast neoplasms - genetics (9) 9
neoadjuvant chemotherapy (9) 9
triple negative breast neoplasms - drug therapy (9) 9
medicine & public health (8) 8
mutation (8) 8
survival (8) 8
contrast-enhanced mri (7) 7
dce-mri (7) 7
neoplasm staging (7) 7
therapy (7) 7
triple negative breast neoplasms - pathology (7) 7
tumors (7) 7
analysis (6) 6
antineoplastic agents - therapeutic use (6) 6
expression (6) 6
magnetic resonance imaging (6) 6
metastasis (6) 6
molecular targeted therapy (6) 6
patients (6) 6
reproducibility of results (6) 6
research (6) 6
sensitivity and specificity (6) 6
tamoxifen (6) 6
treatment response (6) 6
abridged index medicus (5) 5
aged, 80 and over (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
antineoplastic combined chemotherapy protocols - therapeutic use (5) 5
cell line, tumor (5) 5
clinical trials (5) 5
diagnosis (5) 5
health aspects (5) 5
metastases (5) 5
neoadjuvant therapy (5) 5
phosphatidylinositol 3-kinase (5) 5
receptor, erbb-2 - genetics (5) 5
receptor, erbb-2 - metabolism (5) 5
risk factors (5) 5
solid tumors (5) 5
trastuzumab (5) 5
women (5) 5
care and treatment (4) 4
diffusion (4) 4
dose-response relationship, drug (4) 4
endocrine therapy (4) 4
gene expression (4) 4
image enhancement - methods (4) 4
image registration (4) 4
magnetic resonance imaging - methods (4) 4
male (4) 4
phosphatidylinositol 3-kinases - genetics (4) 4
pik3ca mutations (4) 4
prognosis (4) 4
receptors, estrogen - genetics (4) 4
recurrence (4) 4
safety (4) 4
skin and connective tissue diseases (4) 4
toxicity (4) 4
triple negative breast neoplasms - genetics (4) 4
triple negative breast neoplasms - mortality (4) 4
validation (4) 4
1-phosphatidylinositol 3-kinase (3) 3
adjuvant treatment (3) 3
algorithms (3) 3
animals (3) 3
antibodies, monoclonal, humanized - administration & dosage (3) 3
antineoplastic combined chemotherapy protocols - administration & dosage (3) 3
antitumor activity (3) 3
area under curve (3) 3
biomarkers (3) 3
biomarkers, tumor (3) 3
breast - pathology (3) 3
breast neoplasms - diagnosis (3) 3
breast neoplasms - diagnostic imaging (3) 3
cancer research (3) 3
cell lung-cancer (3) 3
cells (3) 3
combination (3) 3
cr bolus-tracking (3) 3
diffusion-weighted mri (3) 3
erbb-2 protein (3) 3
estrogen (3) 3
fluorodeoxyglucose f18 (3) 3
identification (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Cancer, ISSN 0008-543X, 01/2015, Volume 121, Issue 1, pp. 8 - 16
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 2014, Volume 20, Issue 4, pp. 782 - 790
Journal Article
CLINICAL CANCER RESEARCH, ISSN 1078-0432, 01/2017, Volume 23, Issue 1, pp. 26 - 34
Purpose: Alpelisib, a selective oral inhibitor of the class I PI3K catalytic subunit p110 alpha, has shown synergistic antitumor activity with endocrine... 
ACTIVATION | NVP-BYL719 | PIK3CA MUTATIONS | PI3K | ONCOLOGY | PHOSPHATIDYLINOSITOL 3-KINASE | GROWTH | ESTROGEN DEPRIVATION | RESISTANCE | ALPHA | TUMORS | Triazoles - administration & dosage | Receptors, Estrogen - metabolism | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Thiazoles - administration & dosage | Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Receptor, Fibroblast Growth Factor, Type 1 - genetics | Biomarkers, Tumor | Breast Neoplasms - metabolism | Nitriles - administration & dosage | Neoplasm Metastasis | DNA Mutational Analysis | Adult | Female | Aromatase Inhibitors - administration & dosage | Receptors, Estrogen - genetics | In Situ Hybridization, Fluorescence | Treatment Outcome | Breast Neoplasms - drug therapy | Phosphatidylinositol 3-Kinases - genetics | Maximum Tolerated Dose | Breast Neoplasms - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Cell Line, Tumor | Aged | Mutation | Neoplasm Staging | Letrozole | Therapy | Toxicity | p53 Protein | Exanthema | Clinical trials | Metastasis | K-Ras protein | Metastases | Gene sequencing | Anticancer properties | Hyperglycemia | Safety engineering | Catalysis | Fibroblast growth factor receptor 1 | Deoxyribonucleic acid--DNA | Diarrhea | Endocrine therapy | Fatigue | Nausea | Breast cancer | Patients | ErbB-2 protein | 1-Phosphatidylinositol 3-kinase | Inhibitors | Experimental design | Breast | Antitumor activity | Tumors | DNA sequencing | Cancer
Journal Article
Current Breast Cancer Reports, ISSN 1943-4588, 9/2014, Volume 6, Issue 3, pp. 154 - 158
Triple-negative breast cancers (TNBCs) are a group of aggressive breast cancers with a greater incidence of relapse, stage-for-stage, than ER/PR-positive and... 
Medicine & Public Health | Targeted therapy | Oncology | Internal Medicine | Gene expression profiles | TNBC | Surgical Oncology | Triple-negative breast cancer | Chemotherapy | Breast cancer | Gene expression | Analysis | Cancer | targeted therapy | Triple negative breast cancer | gene expression profiles
Journal Article
Magnetic Resonance in Medicine, ISSN 0740-3194, 04/2014, Volume 71, Issue 4, pp. 1592 - 1602
Journal Article
Journal of Clinical Oncology, ISSN 0732-183X, 2014, Volume 32, Issue 12, pp. 1202 - 1209
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 08/2017, Volume 23, Issue 15, pp. 4035 - 4045
Purpose: Because of inherent disease heterogeneity, targeted therapies have eluded triple-negative breast cancer (TNBC), and biomarkers predictive of treatment... 
TUMOR-INFILTRATING LYMPHOCYTES | MAMMALIAN TARGET | SURVIVAL | CHEMOSENSITIVITY | ALIGNMENT | ONCOLOGY | PROGRAMS | CLINICAL-TRIALS | FRAMEWORK | PATTERNS | CHEMOTHERAPY | DNA Damage - drug effects | Humans | Middle Aged | Paclitaxel - adverse effects | Treatment Outcome | Everolimus - administration & dosage | Triple Negative Breast Neoplasms - drug therapy | Cisplatin - administration & dosage | Drug-Related Side Effects and Adverse Reactions - pathology | Receptors, Androgen - genetics | Triple Negative Breast Neoplasms - genetics | Ki-67 Antigen - genetics | Lymphocytes, Tumor-Infiltrating - pathology | Drug-Related Side Effects and Adverse Reactions - genetics | Everolimus - adverse effects | Triple Negative Breast Neoplasms - pathology | Cisplatin - adverse effects | Adult | Female | High-Throughput Nucleotide Sequencing | Mutation | Neoplasm Staging | Paclitaxel - administration & dosage | TOR protein | Mesenchyme | DNA damage | Transaminase | Anticancer properties | Randomization | Lymphocytes | Surgery | Paclitaxel | Bioindicators | Deoxyribonucleic acid--DNA | Neutropenia | Mucositis | Tumor-infiltrating lymphocytes | Decision making | Exploration | Breast cancer | Patients | Cisplatin | Polymerase chain reaction | Correlation analysis | Biomarkers | Breast | Antitumor activity | Cancer | mTOR inhibitor | breast cancer | chemotherapy
Journal Article
Clinical Cancer Research, ISSN 1078-0432, 07/2017, Volume 23, Issue 14, pp. 3520 - 3528
Purpose: This phase Ib study was designed to determine the MTD, safety, preliminary efficacy, and pharmacokinetics of the HER3 (ErbB3) mAb SAR256212 in... 
CELL LUNG-CANCER | ACTIVATION | ERBB3 | ONCOLOGY | PATHWAY | PHOSPHATIDYLINOSITOL 3-KINASE | TYROSINE KINASE | EPIDERMAL-GROWTH-FACTOR | MUTATIONS | UP-REGULATION | METASTATIC COLORECTAL-CANCER | Antibodies, Neutralizing - administration & dosage | Quinoxalines - adverse effects | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Class I Phosphatidylinositol 3-Kinases - genetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Class I Phosphatidylinositol 3-Kinases - immunology | Dose-Response Relationship, Drug | Antibodies, Neutralizing - immunology | Neoplasms - genetics | Receptor, ErbB-3 - immunology | Adult | Antibodies, Neutralizing - adverse effects | Female | Quinoxalines - pharmacokinetics | Quinoxalines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Receptor, ErbB-3 - antagonists & inhibitors | Receptor, ErbB-3 - genetics | Class I Phosphatidylinositol 3-Kinases - antagonists & inhibitors | Sulfonamides - pharmacokinetics | Neoplasms - drug therapy | Maximum Tolerated Dose | Antibodies, Monoclonal - administration & dosage | Neoplasms - immunology | Sulfonamides - adverse effects | Aged | Mutation | Neoplasms - pathology | Sulfonamides - administration & dosage | Intravenous administration | Toxicity | Exanthema | Dosage | Metastases | Safety engineering | Toxic diseases | Safety | Drug dosages | Pharmacodynamics | Diarrhea | Pharmacology | ErbB-3 protein | Disease control | Patients | Hypotension | Constraining | 1-Phosphatidylinositol 3-kinase | Side effects | Inhibitors | Experimental design | Monoclonal antibodies | Solid tumors | Pharmacokinetics | Tumors | Cancer | Index Medicus
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 02/2019, Volume 380, Issue 8, pp. 741 - 751
In an extension of a basket trial focusing on triple-negative breast cancer, patients who received sacituzumab govitecan, an antibody–drug conjugate, had a... 
CAPECITABINE | MEDICINE, GENERAL & INTERNAL | SN-38 | MONOTHERAPY | MANAGEMENT | THERAPY | CONJUGATE | OPEN-LABEL | PHASE-3 | TROP-2 | ACCELERATED APPROVAL | Irinotecan - administration & dosage | Humans | Middle Aged | Cell Adhesion Molecules - antagonists & inhibitors | Male | Antineoplastic Agents - therapeutic use | Diarrhea - chemically induced | Triple Negative Breast Neoplasms - drug therapy | Dose-Response Relationship, Drug | Antineoplastic Agents - adverse effects | Aged, 80 and over | Immunoconjugates - therapeutic use | Adult | Female | Neutropenia - chemically induced | Camptothecin - analogs & derivatives | Immunoconjugates - adverse effects | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Antigens, Neoplasm | Camptothecin - therapeutic use | Anemia - chemically induced | Survival Rate | Triple Negative Breast Neoplasms - mortality | Irinotecan - adverse effects | Progression-Free Survival | Aged | Infusions, Intravenous | Complications and side effects | Anemia | Dosage and administration | Breast cancer | Drug therapy | Risk factors | Antibody-drug conjugates | Data analysis | Nuclear magnetic resonance--NMR | Medical imaging | Body weight | Metastasis | FDA approval | Cancer therapies | Patients | Cell surface | Metastases | Chemotherapy | Medical prognosis | Response rates | Monoclonal antibodies | Solid tumors | Drug dosages | Neutropenia | Tumors | Index Medicus | Abridged Index Medicus
Journal Article